» Articles » PMID: 28214989

Exposure-response Analyses of Blood Pressure and Heart Rate Changes for Methylphenidate in Healthy Adults

Overview
Publisher Springer
Specialty Pharmacology
Date 2017 Feb 20
PMID 28214989
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the study was to evaluate the exposure-response (E-R) relationships of blood pressure (BP) and heart rate (HR) changes in healthy adults taking methylphenidate (MPH). Intensive time profiles of BP and HR from healthy adults in placebo and MPH treatment arms of seven clinical trials from the FDA internal database were utilized for this analysis. The analysis model contains a circadian component for placebo effect and an E-R component to describe drug effect. Internal validation was performed using goodness-of-fit plots and visual predictive check. A meta-database based on a systemic literature search was constructed and used for external validation of the developed models. We found that circadian models could quantify the time profiles of BP/HR in placebo arms. Linear models could describe the correlations between MPH concentrations, and BP/HR changes. The BP and HR changes were highly dependent on the shapes of MPH pharmacokinetic (PK) profiles without an apparent time delay. MPH has the greatest effect on HR, followed by systolic BP, and diastolic BP. Internal validation revealed that the developed models could adequately describe the circadian rhythms of HR and BP in placebo arms and the E-R relationships of MPH. External validation showed the models had good predictive capability of the literature data. In conclusion, the developed models adequately characterized the circadian rhythm and the MPH induced effects on BP and HR. The changes in BP and HR were highly correlated with MPH blood levels with no apparent delay. The time courses of BP and HR are similar to the MPH PK profiles. As a result, the immediate-release formulation may yield larger maximum BP and HR effect than the extended-release formulation under similar dose.

Citing Articles

Home-based tDCS for apathy in Alzheimer's disease: a protocol for a randomized double-blinded controlled pilot study.

Teixeira A, Martins L, Cordeiro T, Jose L, Suchting R, Holmes H Pilot Feasibility Stud. 2023; 9(1):74.

PMID: 37147739 PMC: 10161588. DOI: 10.1186/s40814-023-01310-5.


Quantitative Characterization of the Smoothness of Extended-release Methylphenidate Pharmacokinetic Profiles.

Po M, Gomeni R, Incledon B Innov Clin Neurosci. 2022; 19(7-9):32-37.

PMID: 36204174 PMC: 9507140.


CYP2A6 and GABRA2 Gene Polymorphisms are Associated With Dexmedetomidine Drug Response.

Fang C, Ouyang W, Zeng Y, Pei Q, Xia Y, Luo S Front Pharmacol. 2022; 13:943200.

PMID: 35873555 PMC: 9301121. DOI: 10.3389/fphar.2022.943200.


Novel Formulations of ADHD Medications: Stimulant Selection and Management.

Childress A Focus (Am Psychiatr Publ). 2021; 19(1):31-38.

PMID: 34483764 PMC: 8412159. DOI: 10.1176/appi.focus.20200032.


Revisiting Apathy in Alzheimer's Disease: From Conceptualization to Therapeutic Approaches.

Teixeira A, Gonzales M, de Souza L, Weisenbach S Behav Neurol. 2021; 2021:6319826.

PMID: 34394772 PMC: 8356015. DOI: 10.1155/2021/6319826.


References
1.
Reiz J, Donnelly G, Michalko K . Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults. Clin Ther. 2008; 30(1):59-69. DOI: 10.1016/j.clinthera.2008.01.002. View

2.
Semeijn E, Kooij J, Comijs H, Michielsen M, Deeg D, Beekman A . Attention-deficit/hyperactivity disorder, physical health, and lifestyle in older adults. J Am Geriatr Soc. 2013; 61(6):882-887. DOI: 10.1111/jgs.12261. View

3.
Srinivas N, Hubbard J, Korchinski E, Midha K . Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm Res. 1993; 10(1):14-21. DOI: 10.1023/a:1018956526016. View

4.
Falkner B, Gidding S, Ramirez-Garnica G, Wiltrout S, West D, Rappaport E . The relationship of body mass index and blood pressure in primary care pediatric patients. J Pediatr. 2006; 148(2):195-200. DOI: 10.1016/j.jpeds.2005.10.030. View

5.
Wargin W, Patrick K, Kilts C, Gualtieri C, Ellington K, Mueller R . Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther. 1983; 226(2):382-6. View